Loading...
Market
What will be Lantheus' market share in Alzheimer's diagnostics by end of 2026?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Industry reports or market analysis publications
Story
Lantheus Acquires Life Molecular Imaging for $350 Million, Adding Neuraceq to Alzheimer's Diagnostics
Jan 13, 2025, 06:34 AM
Lantheus Holdings Inc. has agreed to acquire Life Molecular Imaging for an upfront payment of $350 million, with potential additional payments of up to $400 million based on future sales milestones. The acquisition aims to bolster Lantheus' position in the growing Alzheimer's disease radiodiagnostic market by adding Neuraceq, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer's disease. The transaction is expected to enhance Lantheus' growth profile and establish a commercial Alzheimer's disease franchise. Life Healthcare Group Holdings, the current owner of Life Molecular Imaging, plans to return the net proceeds from the upfront payment to shareholders within 12 months of the deal's completion, expected in the second half of 2025.
View original story
Similar markets
No • 50%
Yes • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes, both an imaging agent and software/service • 25%
Yes, a new imaging agent • 25%
Yes, a new software or service • 25%
No new product/service • 25%
More than 20% • 25%
10% to 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
Rejected by FDA • 25%
Withdrawn by manufacturer • 25%
FDA approved and in market • 25%
Pending approval • 25%
Increase by 10% to 20% • 25%
Remain within ±10% • 25%
Decrease by more than 10% • 25%
Increase by more than 20% • 25%
Decreases by more than 10% • 25%
Increases by more than 10% • 25%
Other • 25%
Remains within 10% of current share • 25%
Yes • 50%
No • 50%
Donanemab leads • 25%
Both have equal share • 25%
Leqembi leads • 25%
Other treatments lead • 25%